Absorption, distribution, metabolism and excretion of daily oral doses of [14C]methyl parathion in hens

被引:21
|
作者
Abu-Qare, AW [1 ]
Abdel-Rahman, AA [1 ]
Ahmad, H [1 ]
Kishk, AM [1 ]
Abou-Donia, MB [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
关键词
methyl parathion; p-nitrophenol; pharmacokinetics; hens; organophosphates;
D O I
10.1016/S0378-4274(01)00409-X
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Adult hens were given oral daily doses of 2 mg (2 muC(i))/kg/day (14% of oral LD50 in male rats) of [C-14]methyl parathion (O,O-dimethyl O-4-nitrophenyl phosphorothioate) for 10 consecutive days. Five treated hens were sacrificed at 1, 2, 4, 8, 12, 24, and 48 h after the last dose. Methyl parathion was absorbed from the gastrointestinal tract and distributed rapidly. Maximum radioactivity was detected in tissues within 8 h of dosing, (ng methyl parathion equivalent/g fresh tissue or ml plasma): Plasma (189.2), liver (94.7), kidney (146.2), brain (61.4), gastrointestinal tissues (106.7). Methyl parathion was detected in the plasma, kidney and liver, while methyl parathion metabolite p-nitrophenol was detected in the liver and in the kidney. Elimination of methyl parathion from plasma was monophasic with a terminal half-life of 17.5 h, corresponding to an elimination rate constant of 0.039 ng/hr. Most of the absorbed radioactivity was excreted in the combined fecal-urine excreta (98%). Analysis of the metabolites in the excreta revealed that non-conjugated metabolites accounted for 13% of the total excretion. Conjugated metabolites accounted for 87% of the total excretion; of that, 6% as p-nitrophenyl-glucoronide conjugate, 7% as p-nitrophenyl-sulfate conjugate, 23% as bound hot sulfric acid hydrolyzable residues, and 51% as water soluble metabolites. The presence of majority of radioactivity in the excreta as conjugated metabolites indicates that determining only unbound p-nitrophenol as a biological marker for methyl parathion exposure underestimates total fecal-urine excretion of p-nitrophenol. The slow elimination rate of methyl parathion is significant, since hens are more comparable to humans with respect to their cytochrome P450 activities. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
    Ma, Sheng
    Yi, Ling
    Bian, Yicong
    Lv, Binhua
    Zhang, Cong
    Li, Chengwei
    Zhang, Hua
    Miao, Liyan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [22] Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans
    Ong, Voon
    Wills, Sarah
    Watson, Deborah
    Sandison, Taylor
    Flanagan, Shawn
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [23] A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14C]Seletalisib (UCB5857) in Healthy Subjects
    Helmer, Eric
    Nicolas, Jean-Marie
    Long, Jeff
    Roffel, Ad F.
    Jones, Emma
    Chanteux, Hugues
    Diaz, Nieves
    Garratt, Holly
    Bosje, Tjerk
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12) : 1582 - 1590
  • [24] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Liao, Mingxiang
    Watkins, Simon
    Nash, Eileen
    Isaacson, Jeff
    Etter, Jeff
    Beltman, Jeri
    Fan, Rong
    Shen, Li
    Mutlib, Abdul
    Kemeny, Vendel
    Papai, Zsuzsanna
    van Tilburg, Pascal
    Xiao, Jim J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 765 - 775
  • [25] Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
    Mingxiang Liao
    Simon Watkins
    Eileen Nash
    Jeff Isaacson
    Jeff Etter
    Jeri Beltman
    Rong Fan
    Li Shen
    Abdul Mutlib
    Vendel Kemeny
    Zsuzsanna Pápai
    Pascal van Tilburg
    Jim J. Xiao
    Investigational New Drugs, 2020, 38 : 765 - 775
  • [26] Absorption, Metabolism, and Excretion of [14C]-Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects
    Xie, Lijun
    Xu, Yanjun
    Liu, Wei
    Zhou, Chen
    Guo, Lian
    Zhou, Sufeng
    Zhang, Chen
    Chen, Juan
    Zhu, Bei
    Ding, Sijia
    Li, Huan
    Zhang, Lingling
    Wang, Li
    Xu, Lingmei
    Shao, Feng
    Wang, Lu
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (10): : 1115 - 1122
  • [27] ABSORPTION AND DISTRIBUTION OF ULTRATRACE EXOGENOUS 14C UREA IN RATS
    Wang, Li
    Shen, Hongtao
    Tang, Junsen
    Zhang, Guofeng
    Qi, Linjie
    Chen, Dingxiong
    Wu, Kaiyong
    Han, Xinyi
    Ouyang, He
    He, Yun
    Yang, Pucheng
    Zhang, Xue
    Xia, Chunbo
    RADIOCARBON, 2024, 66 (05) : 1450 - 1459
  • [28] Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients
    Beale, P
    Judson, I
    Hanwell, J
    Berry, C
    Aherne, W
    Hickish, T
    Martin, P
    Walker, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (01) : 71 - 76
  • [29] Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers
    Stoltz, R
    Parisi, S
    Shah, A
    Macciocchi, A
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2004, 25 (08) : 329 - 337
  • [30] A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans
    Schwab, Dietmar
    Portron, Agnes
    Backholer, Zoe
    Lausecker, Berthold
    Kawashima, Kosuke
    CLINICAL PHARMACOKINETICS, 2013, 52 (06) : 463 - 473